我要投票 foci佛慈在阿胶行业中的票数:125
· 外 推 电 报 ·
2025-03-09 22:53:08 星期日

【foci佛慈是哪个国家的品牌?】

foci佛慈是什么牌子?「foci佛慈」是 兰州佛慈制药股份有限公司 旗下著名品牌。该品牌发源于甘肃,由创始人石爱国在2016期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力foci佛慈品牌出海!通过在本页面挂载foci佛慈品牌的产品链接和联系邮箱,可以提高foci佛慈产品曝光!跨境电商爆单神器,目前只要100元/年哦~

兰州佛慈制药股份有限公司是一家具有近百年制药历史的市属国有控股上市公司和“中华老字号”企业(股票代码002644)。1929年创建于上海。1956年西迁兰州。2011年上市。目前,公司已发展成为集中药材种植与加工、天然药物与保健品研发、中药现代剂型及保健食品生产销售为一体的西北地区中医药行业的骨干企业。

截止目前,公司拥有4个生产基地、1个在建的医药科技工业园和2家全资子公司。拥有总资产100912万元、净资产71823万元。现有员工1400余人,其中各类工程技术人员400余名。拥有25条生产线,全部通过国家GMP认证,本部生产线还通过澳大利亚TGA组织、日本厚生省和乌克兰产品认证局的认证。现有药品生产批准文号345个,拥有定眩丸、参茸固本还少丸等10个独家产品,1个国家中药保护品种,9项发明专利,常年生产浓缩丸、大蜜丸、片剂等11种剂型的152种中西药产品。佛慈产品以“选材地道、工艺精良、疗效确切、服用方便”享誉中外。“佛慈”牌六味地黄丸、杞菊地黄丸、桂附地黄丸、逍遥丸、香砂养胃丸等系列产品多次被评为“甘肃名牌产品”。公司产品领域不断拓展,以阿胶、本草饮品“肖助理”等为代表的大健康产品陆续上市。“佛慈”注册商标为驰名保护,“岷山”商标为国家工商总局重点保护商标,“宝炉”、“善舒”为甘肃省著名商标。公司与中国中医科学院、瑞典斯德哥尔摩大学、清华大学、甘肃中医学院等多所国内外一流科研院所建立了良好的合作关系。现有甘肃省现代中药制剂工程技术研究中心和中瑞天然植物药和保健品研究中心两个重点研发平台。在漳县、临潭等地拥有当归规范化种植基地,总种植面积近1万亩。佛慈品牌在国内外具有良好的市场基础和广泛的影响力,国际国内销售网络日益完善,产品行销全国,出口到美国、澳大利亚、日本、香港等27个国家和地区,产品国外认证数、海外商标注册数、出口覆盖面、出口品种数长期位居同行业前列,多年来名列中国中成药出口企业十强。佛慈制药是国内首家申请欧盟药品注册的企业,如果浓缩当归丸在欧盟注册成功,并通过欧盟GMP认证,佛慈产品有望以药品身份进入欧盟市场,同时借此建立中药国际化标准。近期,佛慈制药被国家商务部等部委列入国家“首批中医药服务贸易先行先试骨干企业”名单。

近三年,公司将以新区项目为依托、以构建国际国内销售网络为重点,抢抓机遇,加快发展,力争在三年内实现营业收入10亿元,其中中成药出口1000万美元的目标。

英文翻译:Lanzhou foci Pharmaceutical Co., Ltd. is a municipal state-owned holding listed company and "China time honored brand" enterprise with nearly a hundred years of pharmaceutical history (Stock Code: 002644). Founded in Shanghai in 1929. In 1956, it moved west to Lanzhou. Listed in 2011. At present, the company has developed into a backbone enterprise in the Northwest China traditional Chinese medicine industry, which focuses on the cultivation and processing of traditional Chinese medicine, the research and development of natural drugs and health products, the production and sales of modern dosage forms of traditional Chinese medicine and health food. Up to now, the company has 4 production bases, 1 pharmaceutical science and Technology Industrial Park under construction and 2 wholly-owned subsidiaries. It has total assets of 1009.12 million yuan and net assets of 718.23 million yuan. There are more than 1400 employees, including more than 400 engineering and technical personnel. We have 25 production lines, all of which have passed the national GMP certification. Our production lines have also passed the certification of TGA in Australia, housheng in Japan and Ukrainian product certification authority. At present, there are 345 drug production approval numbers, 10 exclusive products such as Dingxuan pill, Shenrong Guben Huanshao pill, 1 National Traditional Chinese medicine protection variety, 9 invention patents, and 152 kinds of Chinese and Western medicine products with 11 dosage forms such as concentrated pill, big honey pill and tablet. Foci products are well-known at home and abroad for "authentic material selection, excellent technology, accurate curative effect and convenient use". "Foci" brand Liuwei Dihuang pill, Qiju Dihuang pill, Guifu Dihuang pill, Xiaoyao Pill, Xiangsha Yangwei pill and other series of products have been rated as "Gansu famous brand products" for many times. The product field of the company has been expanding, and the large health products represented by donkey hide gelatin and herbal drink "Xiao assistant" have been listed in succession. "Foci" registered trademark is well-known protection, "Minshan" trademark is the key protection trademark of the State Administration for Industry and commerce, "Baolu" and "Shanshu" are famous trademarks of Gansu Province. The company has established good cooperation with many domestic and foreign first-class scientific research institutes, such as Chinese Academy of traditional Chinese medicine, Stockholm University, Tsinghua University, Gansu College of traditional Chinese medicine, etc. At present, there are two key research and development platforms: Gansu Modern Chinese medicine preparation engineering technology research center and Zhongrui natural plant medicine and health product research center. In Zhangxian County, Lintan and other places, there are standardized planting bases for angelica, with a total planting area of nearly 10000 mu. Foci brand has a good market foundation and wide influence at home and abroad. Its international and domestic sales network is increasingly improved. Its products are sold all over the country and exported to 27 countries and regions such as the United States, Australia, Japan and Hong Kong. The number of foreign certification, overseas trademark registration, export coverage and export varieties of its products have long been in the forefront of the same industry. It has been ranked in the middle of China for many years Top 10 pharmaceutical export enterprises. Fosci pharmaceutical is the first enterprise applying for EU drug registration in China. If the concentrated Angelica pill is successfully registered in the EU and passes the EU GMP certification, fosci products are expected to enter the EU market as drugs, and at the same time establish international standards for traditional Chinese medicine. Recently, foci pharmaceutical has been listed in the list of "the first batch of backbone enterprises in the first trial of TCM service trade" by the Ministry of Commerce and other ministries. In the past three years, the company will take the new area project as the support, focus on the construction of international and domestic sales network, seize the opportunity, accelerate the development, and strive to achieve the business income of 1 billion yuan in three years, including the goal of 10 million US dollars for the export of Chinese patent medicine.

本文链接: https://www.waitui.com/brand/f19a649a3.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

2连板国脉科技:公司现已完成部分居家养老场景AI智能体的原型开发 相关技术成果尚未形成商业化收入

36氪获悉,国脉科技(002093.SZ)发布股票交易异常波动公告称,公司关注到部分媒体将公司列为AI智能体(AI Agent)核心龙头股。公司基于在身联网、智慧康养领域的技术积累,现已完成部分居家养老场景AI智能体(AI Agent)的原型开发,目前产品正处于场景适配度优化和用户体验提升阶段,相关技术成果尚未形成商业化收入,短期不会对公司经营业绩产生重大影响。敬请广大投资者关注技术转化周期风险,理性判断投资价值。

54分钟前

我国近半地区提前实现2025年宫颈癌筛查目标

《中国疾病预防控制中心周报》近日公布了2023至2024年我国女性宫颈癌筛查率数据,35至64岁女性的整体筛查率超过50%。2023年,国家卫健委等10部门发布《加速消除宫颈癌行动计划(2023—2030年)》,设定了“到2025年我国适龄妇女宫颈癌筛查覆盖率达到50%、到2030年达到70%”的目标。2023至2024年,中国疾控中心团队在31个省份开展了宫颈癌筛查率调查。结果显示,35至64岁女性的筛查率达到51.5%,20岁及以上女性的筛查率为36.8%。35至64岁女性的整体筛查率已提前实现2025年目标。同时,我国接近一半的地区已提前实现2025年目标。农村筛查覆盖率为48.2%,仍低于2025年目标。(财联社)

54分钟前

中创新航:公司股份获纳入港股通证券名单

36氪获悉,中创新航在港交所公告,根据上交所发布的通知,公司股份已获纳入沪港通下的港股通标的证券名单,并于2025年3月10日起生效。公司董事会认为,公司股份获纳入港股通标的证券名单,将有助于扩大本公司的投资群体,提升公司股票的流动性和市场活跃度。

54分钟前

汤姆猫:公司在AI业务上确立了“AI+IP+Agent”的业务发展方向

36氪获悉,汤姆猫(300459.SZ)发布投资者关系活动记录表公告称,公司在AI业务上确立了“AI+IP+Agent”的业务发展方向,围绕该业务发展方向,公司将从以下几个维度深入推进产品的研发与升级工作:在产品形象上,汤姆猫家族IP包含6个经典的IP角色形象,公司将尽快推出不同IP形象的AI情感陪伴机器人,以满足不同用户对不同IP形象的喜爱需求。基于在多模态技术架构、大模型驱动、任务规划逻辑等方面的深层次共性,公司将在生态协作、情感化任务执行等领域探索与其他AI Agent的结合,将大模型、数据、工具多维一体融合进公司的家庭智能硬件终端上,推动AI从单一功能向“全能伙伴”演进。公司也将与各类机器人相关产业方探讨更丰富的产品形态,例如便于携带的小型机器人、能够运动的机器人等,持续丰富产品形态矩阵,满足用户在不同场景下的使用需求。

54分钟前

长春一东:一汽股权公司拟减持不超3%公司股份

36氪获悉,长春一东公告,一汽股权投资(天津)有限公司计划通过集中竞价交易和大宗交易方式减持公司股份合计不超过424.55万股,即不超过公司总股本的3%。

54分钟前

本页详细列出关于东健阿胶的品牌信息,含品牌所属公司介绍,东健阿胶所处行业的品牌地位及优势。
咨询